Amphastar Pharmaceuticals Inc. (AMPH) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Amphastar Pharmaceuticals... (AMPH)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

38.47

0.55 (1.45%)

At close: Jan 14, 2025, 3:59 PM

38.48

0.03%

After-hours Jan 14, 2025, 06:02 PM EST

undefined% (undefined)

Bid	34.36
Market Cap	1.85B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	3.14
PE Ratio (ttm)	12.25
Forward PE	n/a
Analyst	Buy

Ask	40.48
Volume	410,269
Avg. Volume (20D)	492,044
Open	37.92
Previous Close	37.92
Day's Range	37.26 - 38.92
52-Week Range	34.69 - 56.88
Beta	undefined

About AMPH

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Eno...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Jun 25, 2014

Employees 1,761

Stock Exchange NASDAQ

Ticker Symbol AMPH

Website https://www.amphastar.com

Analyst Forecast

According to 4 analyst ratings, the average rating for AMPH stock is "Buy." The 12-month stock price forecast is $60, which is an increase of 55.97% from the latest price.

Buy 75.00%

Hold 25.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Amphastar Pharmaceuticals Inc. is scheduled to release its earnings on Feb 26, 2025, during market hours.
Analysts project revenue of $192.08M, reflecting a 7.85% YoY growth and earnings per share of 0.96, making a 9.09% increase YoY.

Why Price Moved

2 months ago · Source

-13.69%

Amphastar Pharma shares are trading lower after th... Unlock content with Pro Subscription

5 months ago · Source

+13.29%

Amphastar Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.

News

1 week ago · seekingalpha.com

Amphastar Pharmaceuticals: Cheap With Caveats

Amphastar Pharmaceuticals' stock has declined over 25% since early November, despite solid earnings and sales growth, presenting a potential buying opportunity. Q3 results were impacted somewhat by th...

1 week ago · zacks.com

New Strong Sell Stocks for January 2nd

AGCO, AMPH and ASC have been added to the Zacks Rank #24 (Strong Sell) List on January 2, 2024.

2 weeks ago · zacks.com

New Strong Sell Stocks for December 31st

AGL, AMPH and CR have been added to the Zacks Rank #24 (Strong Sell) List on December 31, 2024.

2 months ago · seekingalpha.com

Amphastar Pharmaceuticals Inc. (AMPH) Q3 2024 Earnings Call Transcript

2 months ago · zacks.com

Here's What Key Metrics Tell Us About Amphastar (AMPH) Q3 Earnings

Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall S...

2 months ago · zacks.com

Amphastar Pharmaceuticals (AMPH) Lags Q3 Earnings and Revenue Estimates

Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.96 per share, missing the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $1.15 per share a year ago.

2 months ago · zacks.com

Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy?

Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · zacks.com

Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

2 months ago · zacks.com

Will Amphastar (AMPH) Beat Estimates Again in Its Next Earnings Report?

Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.